Literature DB >> 25813389

Therapeutic prospects for migraine: can paradise be regained?

Peter J Goadsby1.   

Abstract

Migraine is a common, complex brain disorder whose biology is becoming better understood. Despite being the most disabling of the neurological disorders on a worldwide basis, headache disorders broadly, and migraine in particular, have poor research funding and a limited academic base. Given a modicum of investment, new targets, such as calcitonin gene-related peptide-based mechanisms, and entirely novel neuromodulation approaches illustrate that much can be done to improve patient care. Genetics and neuroimaging combined with excellent clinical phenotyping and translational neuroscience approaches are set to transform life for a cohort of patients with these common brain disorders.
Copyright © 2013 American Neurological Association.

Entities:  

Mesh:

Year:  2013        PMID: 25813389     DOI: 10.1002/ana.23996

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  10 in total

Review 1.  Targeting CGRP: A New Era for Migraine Treatment.

Authors:  Stephanie Wrobel Goldberg; Stephen David Silberstein
Journal:  CNS Drugs       Date:  2015-06       Impact factor: 5.749

2.  Targeting the central projection of the dural trigeminovascular system for migraine prophylaxis.

Authors:  Simon Akerman; Marcela Romero-Reyes
Journal:  J Cereb Blood Flow Metab       Date:  2017-09-08       Impact factor: 6.200

3.  A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study).

Authors:  Roger K Cady; Peter J McAllister; Egilius L H Spierings; John Messina; Jennifer Carothers; Per G Djupesland; Ramy A Mahmoud
Journal:  Headache       Date:  2014-10-30       Impact factor: 5.887

Review 4.  Treatment of Chronic Migraine with Focus on Botulinum Neurotoxins.

Authors:  Sara M Schaefer; Christopher H Gottschalk; Bahman Jabbari
Journal:  Toxins (Basel)       Date:  2015-07-14       Impact factor: 4.546

5.  Single-pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: evaluation of outcome data for the UK post market pilot program.

Authors:  Ria Bhola; Evelyn Kinsella; Nicola Giffin; Sue Lipscombe; Fayyaz Ahmed; Mark Weatherall; Peter J Goadsby
Journal:  J Headache Pain       Date:  2015-06-03       Impact factor: 7.277

6.  Pituitary adenylate cyclase activating polypeptide and migraine.

Authors:  Alessandro S Zagami; Lars Edvinsson; Peter J Goadsby
Journal:  Ann Clin Transl Neurol       Date:  2014-11-12       Impact factor: 4.511

7.  Ictal lack of binding to brain parenchyma suggests integrity of the blood-brain barrier for 11C-dihydroergotamine during glyceryl trinitrate-induced migraine.

Authors:  Christoph J Schankin; Farooq H Maniyar; Youngho Seo; Shashidar Kori; Michael Eller; Denise E Chou; Joseph Blecha; Stephanie T Murphy; Randall A Hawkins; Till Sprenger; Henry F VanBrocklin; Peter J Goadsby
Journal:  Brain       Date:  2016-05-27       Impact factor: 13.501

Review 8.  PACAP and migraine headache: immunomodulation of neural circuits in autonomic ganglia and brain parenchyma.

Authors:  James A Waschek; Serapio M Baca; Simon Akerman
Journal:  J Headache Pain       Date:  2018-03-13       Impact factor: 7.277

9.  Cross-trait analyses with migraine reveal widespread pleiotropy and suggest a vascular component to migraine headache.

Authors:  Katherine M Siewert; Derek Klarin; Scott M Damrauer; Kyong-Mi Chang; Philip S Tsao; Themistocles L Assimes; George Davey Smith; Benjamin F Voight
Journal:  Int J Epidemiol       Date:  2020-06-01       Impact factor: 7.196

10.  Nociception-specific blink reflex: pharmacology in healthy volunteers.

Authors:  J C A Marin; A R Gantenbein; K Paemeleire; H Kaube; P J Goadsby
Journal:  J Headache Pain       Date:  2015-10-08       Impact factor: 7.277

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.